Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Russia’s Biocad Unveils New Manufacturing Site In North Africa

By Mike Botta | November 29, 2017

Russian biotechnology company Biocad, in collaboration with Moroccan pharmaceutical company Sothema Labs, launched a new manufacturing facility in Morocco to serve the North African market with rituximab and bevacizumab biosimilars, approved in October for the treatment of cancer.

In addition to Morocco, the companies plan to market the biosimilars in Senegal, Gabon, and Côte d’Ivoire.

Biocad estimated the North African market for rituximab, bevacizumab, trastuzumab and other high-tech monoclonal antibody drug products at $220 million, with the individual Moroccan market valued at $40 million.

The collaboration between Biocad and Sothema Labs, which began four years ago, involved technology transfer and validation, stability and quality testing, and product authorization during the period.

According to Biocad, the originating drug is 30 percent more expensive than its new bevacizumab and rituximab biosimilars. The products are expected to go on sale “in the coming days,” Dmitry Morozov, the CEO of Biocad, said. 

“This is the first successful case of transferring technologies of the (monoclonal antibody) drug products manufacturing to North Africa amid the refusal of Western companies to implement such projects,” Morozov said. “Russia, represented by Biocad, helped its partner to launch a high-tech production.” He added that once the manufacturing site reaches its full production capacity, the partners expect to capture more than 50 percent of the relevant cancer drug market.

Meanwhile, Biocad also reached an agreement to manufacture finished dosage products in Algeria “using the production capacities of their strategic partner.” No further details on that agreement were released.

(Source: Biocad)

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Prolific Machines logo.
Prolific Machines enters FDA program to enhance therapeutics manufacturing platform
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE